Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC

Innovent Biologics of Suzhou reported positive data from a Phase III trial of its anti-PD-1 drug, Tyvyt®, as a second line therapy for patients with non-small cell lung cancer. Patients who received Tyvyt® experienced a statistically significant improvement in overall survival compared to those who received docetaxel. Currently, Innovent has three Tyvyt® NDAs under review in China . In addition, the company is conducting more than 20 clinical trials of Tyvyt® in a variety of cancer indications. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //